Department of Bacteriology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Division of Infectious Diseases, University of Pittsburgh School of Medicine, S829 Scaife Hall, 3350 Terrace Street, Pittsburgh, PA 15261, USA; Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Japan; Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan.
Infect Dis Clin North Am. 2020 Dec;34(4):887-902. doi: 10.1016/j.idc.2020.06.002. Epub 2020 Sep 30.
The clinical usefulness of aminoglycosides has been revisited as an effective choice against β-lactam-resistant and fluoroquinolone-resistant gram-negative bacterial infections. Plazomicin, a next-generation aminoglycoside, was introduced for the treatment of complicated urinary tract infections and acute pyelonephritis. In contrast, bacteria have resisted aminoglycosides, including plazomicin, by producing 16S ribosomal RNA (rRNA) methyltransferases (MTases) that confer high-level and broad-range aminoglycoside resistance. Aminoglycoside-resistant 16S rRNA MTase-producing gram-negative pathogens are widespread in various settings and are becoming a grave concern. This article provides up-to-date information with a focus on aminoglycoside-resistant 16S rRNA MTases.
氨基糖苷类药物的临床应用价值已被重新审视,因其可有效对抗β-内酰胺类和氟喹诺酮类耐药的革兰氏阴性菌感染。作为新一代氨基糖苷类药物,普拉佐米星被引入用于治疗复杂性尿路感染和急性肾盂肾炎。然而,细菌通过产生能够赋予高水平和广谱氨基糖苷类耐药性的 16S 核糖体 RNA(rRNA)甲基转移酶(MTases),对包括普拉佐米星在内的氨基糖苷类药物产生了耐药性。携带氨基糖苷类耐药 16S rRNA MTase 的革兰氏阴性病原体广泛存在于各种环境中,这已成为一个严重的问题。本文提供了最新的信息,重点介绍了氨基糖苷类耐药 16S rRNA MTase。